Article Text

Download PDFPDF

379 Epi-RTM P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time
  1. Yogin Patel,
  2. Jaewon Yun,
  3. Melissa Bedard,
  4. Melissa DeFrancesco,
  5. Carson Harms,
  6. Benjamin Harris,
  7. Saeed Azimi,
  8. Ngoc-Han Ha,
  9. Audrey Garces,
  10. Shobha Potluri,
  11. Gary Lee and
  12. Suman Vodnala
  1. Lyell Immunopharma, South San Francisco, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) can mediate durable responses in advanced solid tumors.1–3 One of the challenges with current TIL productions is long duration of culture times (4–6 weeks) that reduce TIL stemness and TCR diversity through progressive differentiation. Literature suggests that shorter culture duration is correlated with longer telomere length, increased stemness, improved persistence, and positive clinical outcomes in metastatic melanoma patients.4 5 Therefore, strategies that shorten the culture time without adversely affecting stemness, or polyclonality while maintaining high expansion success rates are warranted. Previously, we have shown that TIL expanded with the Epi-R P1 manufacturing protocols results in TIL with improved stemness, antitumor function, and maintenance of polyclonality. Epi-RTM P2 is an improved TIL expansion process that reduces the TIL culture duration to less than 3 weeks without impacting the quality of TIL.

Methods TIL products were produced from 12 tumor tissues across 3 different tumor types (melanoma, lung and colorectal cancer) treated with or without checkpoint inhibitors [CPI] using the Epi-R P2 and Epi-R P1 protocols. Characteristics of the resulting products (Epi-R P2 and Epi-R P1, respectively) were compared using a matrix of assays involving flow cytometry, co-culturing with autologous tumor cell line, and TCR beta sequencing.

Results Epi-R P2 protocol resulted in significantly higher TIL yields at the end of the first expansion step: Epi-R P2 REP1 phase (8 to 10 days) compared to Epi-R P1 pre-REP phase (10 to 14 days) in 3 different tumor types. After a second expansion step, Epi-R P2 protocol yielded an average of 60 billion T cells. TIL products derived from Epi-R P2 protocols resulted in maintenance of similar preferential skewing of CD8+ T cells compared to Epi-R P1 products and also preserved similar or better stemness qualities. Epi-R P2 significantly reduced terminally differentiated cells and increased the magnitude of most frequent clones present in the baseline tumor. Furthermore, Epi-R P2 process is scalable and can be implemented for manufacturing TIL while maintaining stemness and preservation of putative tumor-reactive clones.

Conclusions Results from research and large-scale Epi-RTM P2 demonstrated successful TIL expansion from both immunologically hot and cold tumors in less than 3 weeks. Compared to the previous Epi-R process, Epi-RTM P2 maintained a greater proportion of stem-like T cells and increased the magnitude of most frequent clones that were present in the baseline tumor.


  1. Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27:1410–1418.

  2. Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res. 2021;27:5289–5298.

  3. van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8:e000848.

  4. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–4557.

  5. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008 Oct;31(8):742–51. doi: 10.1097/CJI.0b013e31818403d5. PMID: 18779745; PMCID: PMC2614999.

Ethics Approval Research was performed with tissues obtained from patients through a procurement protocol approved by WCG IRB, tracking number 20210857

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.